{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:48:47Z","timestamp":1767703727677,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jaad.2019.08.019","type":"journal-article","created":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T17:56:14Z","timestamp":1565459774000},"page":"389-397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study"],"prefix":"10.1016","volume":"82","author":[{"given":"Amy S.","family":"Paller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily M.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raul","family":"de Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Paris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuoshun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Barcellona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Maes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loretta","family":"Fiorillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jaad.2019.08.019_bib1","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1525-1470.2000.01746.x","article-title":"A comparative study of pediatric onset psoriasis with adult onset psoriasis","volume":"17","author":"Raychaudhuri","year":"2000","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.08.019_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","article-title":"Psoriasis in children and adolescents: diagnosis, management and comorbidities","volume":"17","author":"Bronckers","year":"2015","journal-title":"Paediatr Drugs"},{"issue":"10","key":"10.1016\/j.jaad.2019.08.019_bib3","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1610-0387.2010.07507.x","article-title":"Juvenile psoriasis and its clinical management: a European expert group consensus","volume":"8","author":"Stahle","year":"2010","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"10.1016\/j.jaad.2019.08.019_bib4","first-page":"187","article-title":"Prevalence of psoriasis in children and adolescents in the United States: a claims-based analysis","volume":"17","author":"Paller","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.08.019_bib5","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jaad.2009.07.029","article-title":"Incidence of psoriasis in children: a population-based study","volume":"62","author":"Tollefson","year":"2010","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.08.019_bib6","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1525-1470.2001.018003188.x","article-title":"Childhood psoriasis: a clinical review of 1262 cases","volume":"18","author":"Morris","year":"2001","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.08.019_bib7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2340\/00015555-2600","article-title":"Health-related quality of life in children and adolescents with psoriasis: a systematic review and meta-analysis","volume":"97","author":"Randa","year":"2017","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"10.1016\/j.jaad.2019.08.019_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/bjd.12371","article-title":"Psychological differences between early- and late-onset psoriasis: a study of personality traits, anxiety and depression in psoriasis","volume":"169","author":"Remrod","year":"2013","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.08.019_bib9","first-page":"147","article-title":"Update on pediatric psoriasis","volume":"95","author":"Silverberg","year":"2015","journal-title":"Cutis"},{"issue":"1","key":"10.1016\/j.jaad.2019.08.019_bib10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1001\/archdermatol.2011.263","article-title":"Trends in pediatric psoriasis outpatient health care delivery in the United States","volume":"148","author":"Vogel","year":"2012","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.08.019_bib11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/pde.12072","article-title":"Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States","volume":"30","author":"Mercy","year":"2013","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jaad.2019.08.019_bib12","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jaad.2019.08.019_bib13","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/1346-8138.13829","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: efficacy, safety and tolerability results from a phase 2b randomized controlled trial","volume":"44","author":"Ohtsuki","year":"2017","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2019.08.019_bib14","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2019.08.019_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/jcph.1029","article-title":"Pharmacokinetics, immunogenicity, and efficacy of etanercept in pediatric patients with moderate to severe plaque psoriasis","volume":"58","author":"Langley","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"S10","key":"10.1016\/j.jaad.2019.08.019_bib16","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor: improvements in nail and scalp psoriasis and Psoriasis Area and Severity Index in patients with moderate to severe plaque psoriasis [abstract 2889]","volume":"67","author":"Papp","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.jaad.2019.08.019_bib17","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2019.08.019_bib18","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaad.2017.01.052","article-title":"Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for \u2265156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)","volume":"77","author":"Crowley","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.08.019_bib19","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3109\/09546634.2014.996515","article-title":"Methotrexate in pediatric plaque-type psoriasis: long-term daily clinical practice results from the Child-CAPTURE registry","volume":"26","author":"van Geel","year":"2015","journal-title":"J Dermatol Treat"},{"issue":"5","key":"10.1016\/j.jaad.2019.08.019_bib20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/pde.12940","article-title":"Effectiveness and safety of acitretin in children with plaque psoriasis: a multicenter retrospective analysis","volume":"33","author":"Di Lernia","year":"2016","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2019.08.019_bib21","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3109\/09546634.2015.1120852","article-title":"Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: a multicentric retrospective analysis","volume":"27","author":"Di Lernia","year":"2016","journal-title":"J Dermatol Treat"},{"issue":"6","key":"10.1016\/j.jaad.2019.08.019_bib22","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/1346-8138.13713","article-title":"Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: a multicenter, cohort study","volume":"44","author":"Ergun","year":"2017","journal-title":"J Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2019.08.019_bib23","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jamadermatol.2017.3029","article-title":"Safety of systemic agents for the treatment of pediatric psoriasis","volume":"153","author":"Bronckers","year":"2017","journal-title":"JAMA Dermatol"},{"year":"2017","series-title":"Enbrel [package insert]","key":"10.1016\/j.jaad.2019.08.019_bib24"},{"year":"2018","series-title":"Remicade (infliximab) [package insert]","key":"10.1016\/j.jaad.2019.08.019_bib25"},{"issue":"4","key":"10.1016\/j.jaad.2019.08.019_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","article-title":"Immunogenicity of biologics in chronic inflammatory diseases: a systematic review","volume":"31","author":"Strand","year":"2017","journal-title":"Biodrugs"},{"key":"10.1016\/j.jaad.2019.08.019_bib27","first-page":"43","article-title":"Psoriasis in childhood: effective strategies to improve treatment adherence","volume":"5","author":"Shah","year":"2015","journal-title":"Psoriasis (Auckl)"},{"key":"10.1016\/j.jaad.2019.08.019_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12887-015-0447-z","article-title":"Children's perceptions about medicines: individual differences and taste","volume":"15","author":"Mennella","year":"2015","journal-title":"BMC Pediatr"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219325666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962219325666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:52:30Z","timestamp":1759272750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962219325666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0190962219325666"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2019.08.019","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2019.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}